SCOT-HEART (Scottish COmputed Tomography of the HEART) and PROMISE (PROspective Multicenter Imaging Study for Evaluation of chest pain) represent the 2 largest and most comprehensive cardiovascular imaging outcome trials in patients with stable chest pain and provide significant insights into patient diagnosis, management, and outcomes. These trials are particularly timely, given the well-recognized knowledge gaps and widespread use of noninvasive imaging. The overall goal of this review is to distill the data generated from these 2 pivotal trials to better inform the practicing clinician in the selection of noninvasive testing for stable chest pain. Similarities and differences between SCOT-HEART and PROMISE are highlighted, and clinical and practical implications are discussed. Both trials show that coronary computed tomography angiography should have a greater role in the diagnostic pathway of patients with stable chest pain. (J Am Coll Cardiol 2016;67:843-52)
A ngina is highly prevalent in the general population and increases with age in both sexes, occurring in 10% to 11% of those >80 years of age (1) . New-onset, stable chest pain is a common clinical problem that results in approximately 4 million stress tests annually in the United States (2) .
At the same time, patients diagnosed with noncardiac chest pain account for one-third of patients who subsequently die from cardiovascular disease or have an acute coronary syndrome during 5 years of follow-up (3) . Therefore, despite several decades of noninvasive cardiovascular testing development and experience, improved diagnostic accuracy and risk stratification is still needed (4).
Significant variations in diagnostic strategies between European countries and the United States are well-documented and may be related to differences in health care systems, access to testing technologies, and risk tolerance (2, 5, 6) . Furthermore, variation may be explained by the limited information on healthrelated outcomes in this stable, undiagnosed population, and there is little consensus about which test is preferable, or even when one is required (7-9).
Major U.S. and European guidelines differ fairly substantially in their fundamental approach to determining the pre-test probability (PTP) of coronary artery disease (CAD) in symptomatic patients and how to proceed with test selection. Furthermore, both U.S. and European measures markedly overestimate PTP rates (10).
To address these issues systematically, 2 large, multicenter, open-label, randomized controlled trials explored the diagnostic evaluation of patients with symptoms that may represent coronary heart disease (CHD). The SCOT-HEART (Scottish COmputed Tomography of the HEART) (11) and PROMISE (PROspective Multicenter Imaging Study for Evaluation of chest pain) (12) trials sought to address an evidence between SCOT-HEART and PROMISE make it tempting to combine these studies (14, 15) .
However, several salient differences in study populations and endpoints are critical to understanding the implications of each.
How do we best incorporate the results of 2 pivotal trials, SCOT-HEART and PROMISE, into current practice to provide optimal care for our patients? This review aims to provide a context for approaching noninvasive imaging by:
1. Describing the historically unmet clinical need for outcomes research in cardiovascular imaging;
Enumerating similarities and differences between
SCOT-HEART and PROMISE;
3. Briefly summarizing other very recent trial results or ongoing trials; and 4. Providing a unified set of conclusions, drawing upon the findings of both SCOT-HEART and PROMISE.
A HISTORICAL UNMET NEED FOR CARDIOVASCULAR IMAGING OUTCOMES TRIALS
Despite the routine use of noninvasive testing for patients with stable chest pain of suspected cardiac etiology over the last several decades, until 2015, no large-scale randomized trial had evaluated the diagnosis, management, and outcomes of these patients.
Most recent clinical trials for CCTA focused on assessing its accuracy and comparability for identification of CHD (16, 17) , or its effect on management of low-risk patients presenting to the emergency department with acute chest pain (18 Clinical Implications From SCOT-HEART and PROMISE Their results may also now be critically evaluated in the context of this model ( Figure 1 ).
KEY FINDINGS FROM SCOT-HEART AND PROMISE.
The SCOT-HEART study enrolled 4 SCOT-HEART AND PROMISE: SIMILARITIES Tables 1 and 2 summarize the similarities between the 2 trials. First, both trials recruited symptomatic Values are mean AE SD or %.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CHD ¼ coronary heart disease; CVD ¼ cardiovascular disease; ECG ¼ electrocardiogram; Echo ¼ echocardiography; MPI ¼ myocardial perfusion imaging; PAD ¼ peripheral arterial disease; other abbreviations as in Table 1 .
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Clinical Implications From SCOT-HEART and PROMISE patients requiring nonemergent evaluation. Second, patients in both trials had a high burden of cardiovascular risk factors, including small numbers of those with prior peripheral and cerebrovascular disease, and were felt to have a 50% chance of having CHD. Consistent with this, nearly one-half of the patients in both trials received aspirin and statin therapy at baseline.
Third, the interventions in both trials were similar: a comparison of CCTA to usual care early in the evaluation of patients with suspected CHD. Importantly, neither included a "no-testing" arm, an option some support because of the trials' low event rates.
Both trials followed patients for up to 4 years (median 20 to 25 months) and had low rates of adverse events attributable to CCTA that, when they did occur, were mild and self-limiting. Both trials saw similar rates of the use of invasive coronary angiography in the CCTA group at 6 weeks (SCOT-HEART, 12%) and 90 days (PROMISE, 12%). CCTA was associated with increased use of percutaneous coronary intervention and coronary artery bypass graft surgery, although this was statistically nonsignificant in SCOT-HEART (p ¼ 0.06).
Fourth, event rates in both trials were low, with large proportions of patients having normal or nearnormal coronary arteries and already receiving excellent preventative therapy at baseline. In SCOT-HEART, the overall rate of all-cause death and nonfatal MI was 2.3% at a median follow-up of 1.7 years (1.35%/year), whereas the overall rate of the same 2 endpoints in PROMISE was 2.2% at 2.1 years (1.05%/year). Although CCTA did not improve the primary endpoint in PROMISE (all-cause death, nonfatal MI, hospitalization for unstable angina, and major procedural complications), its use in both trials was associated with lower MI rates that were of borderline statistical significance. The influence of CCTA use on MI rates is suggested by the divergence of the event curves in SCOT-HEART beginning at 6 weeks, a time point that is attributable to the delay in obtaining and acting on the CCTA result. Indeed, Vs. Main results and conclusions from the SCOT-HEART (Scottish COmputed Tomography of the HEART) and PROMISE (PROspective Multicenter Imaging Study for Evaluation of chest pain) trials. CAD ¼ coronary artery disease; CCTA ¼ coronary computed tomography angiography; ECG ¼ electrocardiography.
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landmark analyses in this trial suggest that CCTA may lead to a halving of MI rates.
SCOT-HEART AND PROMISE: DIFFERENCES
A number of notable differences between the trials are summarized in Tables 1 and 2 . First, PROMISE was larger, included centers over a much larger geographical area in North America, and had broader inclusion criteria, although it did exclude known CHD or a recent CHD evaluation. SCOT-HEART was con- Fifth, PROMISE saw a doubling of coronary revascularization rates in patients randomized to receive CCTA, whereas SCOT-HEART saw an increase of approximately 20%. However, this likely reflects the fact that no patients were scheduled for an invasive coronary angiogram at randomization in PROMISE, whereas 1 in 8 patients in SCOT-HEART were already scheduled for this test. The revascularization rates in SCOT-HEART were nearly twice those in PROMISE, likely reflecting the 2-to 3-fold higher rates of obstructive CAD and the inclusion of patients with more severe symptoms in the SCOT-HEART population. Fordyce et al.
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Clinical Implications From SCOT-HEART and PROMISE Clinical Implications From SCOT-HEART and PROMISE Finally, the 2 trials had markedly different primary and secondary endpoints. SCOT HEART assessed the certainty of the diagnosis of angina due to CHD, whereas PROMISE assessed a composite of major adverse cardiac events and safety. However, both trials assessed a variety of measures of test outcomes along the same hierarchical continuum of diagnostic test performance (19) (Figure 1) . Nevertheless, by assessing changes in diagnostic thinking, the primary endpoint in SCOT-HEART was more upstream and independent of subsequent care choices than in PROMISE. This aspect was examined indirectly in PROMISE by the rate of referral to invasive catheterization. Only PROMISE pre-specified an endpoint of the rate of invasive catheterization, which did not show obstructive CHD and overall radiation exposure. show nonobstructive CAD disease, and many of these patients will not experience an untoward clinical event (24) (25) (26) . However, only an anatomic approach can identify nonobstructive disease, which is associated with event rates similar to obstructive, single-vessel disease (27) . Finally, both trials demonstrate that both anatomic and functional strategies resulted in few safety endpoints related to either testing arm or downstream events, such as cardiac catheterization, and relatively low levels of radiation exposure. These findings are important, given the recent focus on reducing inappropriate cardiac testing to prevent unnecessary risk to patients (2, 28, 29) .
PRACTICAL AND CLINICAL IMPLICATIONS FROM SCOT-HEART AND PROMISE CONTEMPORARY PATIENTS WITH STABLE CHEST PAIN APPEAR TO BE AT LOW RISK OF CLINICAL EVENTS
A CONTINUED ROLE FOR FUNCTIONAL STRESS TESTING. Stress testing will continue to play an important and highly appropriate frontline role in our assessment of stable, symptomatic patients. Tables 1   and 2 .
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